MIRA MIRA Pharmaceuticals, Inc.
Listings ·
Nasdaq told Mira Pharmaceuticals on July 27, 2026 that its common stock no longer meets the $1 minimum bid price. The company has until January 25, 2027 to regain compliance, and it reported a 2025 net loss of $10.4 million on cash used in operations of $4.7 million.
SKNY contributed $5 million in marketable securities to MIRA as a closing condition. MIRA says it believes it has regained compliance with Nasdaq's $2,500,000 equity rule, but the filing gives no share count for the deal.
Nasdaq says MIRA's stockholders' equity of $2,199,750 at December 31, 2024 is below the $2.5 million minimum. The company has until May 23, 2025 to submit a plan, and says a pending acquisition would bring a $5 million capital infusion.
MIRA reported stockholders' equity of $2,199,750 as of December 31, 2024, below the $2.5 million Nasdaq minimum. It has until May 23, 2025 to submit a plan to regain compliance, and its main fix is an acquisition the release says it expects to complete.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $1.7 million | $3.3 million |
| Net income (loss) | -$10.4 million | -$7.9 million |
| Cash from operations | -$4.7 million | -$5.6 million |
| Cash and equivalents | $6.3 million | $2.8 million |
| Short-term investments | $4.7 million |
Our latest story on this, dated Jul 31, 2026: "Mira Pharmaceuticals gets Nasdaq bid price deficiency notice; deadline is January 25, 2027". The story links the filing or release it is based on. Read the story.
MIRA Pharmaceuticals, Inc. trades under the ticker MIRA on NASDAQ.
MIRA Pharmaceuticals, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:K6S; LSX:A3EQWL.
The SEC Central Index Key (CIK) for MIRA Pharmaceuticals, Inc. is 1904286. Its filings are on SEC EDGAR.
42,022,087 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-12.
Our directory records MIRA Pharmaceuticals, Inc. under United States.
Our directory classifies MIRA Pharmaceuticals, Inc. as: Biopharma / pharmaceutical profile checked. This is a directory classification, not a description of the pipeline.
The ISIN recorded for MIRA Pharmaceuticals, Inc. is US60458C1045.
aibio.space lists MIRA Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as FL.
MIRA Pharmaceuticals, Inc. reported a net loss of $10.4 million for the fiscal year ended Dec 31, 2025, and used $4.7 million of cash in operations, per its annual report to the SEC.
$1.7 million in the fiscal year ended Dec 31, 2025, per its annual report.
$8.1 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on MIRA Pharmaceuticals, dated Jul 31, 2026: "Mira Pharmaceuticals gets Nasdaq bid price deficiency notice; deadline is January 25, 2027". Nasdaq told Mira Pharmaceuticals on July 27, 2026 that its common stock no longer meets the $1 minimum bid price. The company has until January 25, 2027 to regain compliance, and it reported a 2025 net loss of $10.4 million on cash used in operations of $4.7 million. Source.
From our story of Jul 31, 2026: The auditor's report on the 2025 financial statements contains an explanatory paragraph on the company's ability to continue as a going concern, and the company says its losses and negative cash flows raise substantial doubt about that ability absent adequate new debt or equity financing. Source.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,2.01,3.02,8.01,9.01). Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,5.02,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 8.01). Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio